ID: MRFR/HC/8603-HCR | 120 Pages | Author: Kinjoll Dey | March 2024
Table of Contents
1. EXECUTIVE SUMMARY
1.1. Market Attractiveness Analysis
1.1.1. Global Daptomycin Market, by Indication
1.1.2. Global Daptomycin Market, by Age group
1.1.3. Global Daptomycin Market, by Strength
1.1.4. Global Daptomycin Market, by Region
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.3. Market Structure
3. RESEARCH METHODOLOGY
3.1. Research Process
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
3.5. Forecast Model
3.6. List of Assumptions
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.2.1. Increasing Complicated Skin & Skin Structure Infections
4.2.2. XXXXXX
4.2.3. XXXXXX
4.3. Restraints
4.3.1. XXXX
4.3.2. XXXX
4.4. Opportunities
4.4.1. Opportunity 1
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis/Supply Chain Analysis
5.2. Porter’s Five Forces Model
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. Impact Analysis of COVID-19 on Anatomic Pathology Market
5.3.1. Impact on Supply Chain
5.3.2. Impact on Pricing
5.3.3. Impact in Major regions (Americas, Europe, Asia-Pacific, Middle East & Africa)
6. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY INDICATION
6.1. Overview
6.2. Complicated Skin Structure Infections
6.3. Bacteremia
6.4. Others
7. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY AGE GROUP
7.1. Overview
7.2. Pediatric
7.3. Adult
8. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY STRENGTH
8.1. Overview
8.2. 350 mg
8.3. 500 mg
9. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY REGION
9.1. Overview
9.2. Americas
9.2.1. Market Estimates & Forecast, by Indication, 2023-2032
9.2.2. Market Estimates & Forecast, by Age group, 2023-2032
9.2.3. Market Estimates & Forecast, by Strength, 2023-2032
9.2.4. Market Estimates & Forecast, by Region, 2023-2032
9.2.4.1. North America
9.2.4.1.1. Market Estimates & Forecast, by Indication, 2023-2032
9.2.4.1.2. Market Estimates & Forecast, by Age group, 2023-2032
9.2.4.1.3. Market Estimates & Forecast, by Strength, 2023-2032
9.2.4.1.4. Market Estimates & Forecast, by Country, 2023-2032
9.2.4.1.4.1. US
9.2.4.1.4.1.1. Market Estimates & Forecast, by Indication, 2023-2032
9.2.4.1.4.1.2. Market Estimates & Forecast, by Age group, 2023-2032
9.2.4.1.4.1.3. Market Estimates & Forecast, by Strength, 2023-2032
9.2.4.1.4.2. Canada
9.2.4.1.4.2.1. Market Estimates & Forecast, by Indication, 2023-2032
9.2.4.1.4.2.2. Market Estimates & Forecast, by Age group, 2023-2032
9.2.4.1.4.2.3. Market Estimates & Forecast, by Strength, 2023-2032
9.2.4.2. Latin America
9.2.4.2.1. Market Estimates & Forecast, by Indication, 2023-2032
9.2.4.2.2. Market Estimates & Forecast, by Age group, 2023-2032
9.2.4.2.3. Market Estimates & Forecast, by Strength, 2023-2032
9.3. Europe
9.3.1. Market Estimates & Forecast, by Indication, 2023-2032
9.3.2. Market Estimates & Forecast, by Age group, 2023-2032
9.3.3. Market Estimates & Forecast, by Strength, 2023-2032
9.3.4. Market Estimates & Forecast, by Region, 2023-2032
9.3.4.1. Western Europe
9.3.4.1.1. Market Estimates & Forecast, by Indication, 2023-2032
9.3.4.1.2. Market Estimates & Forecast, by Age group, 2023-2032
9.3.4.1.3. Market Estimates & Forecast, by Strength, 2023-2032
9.3.4.1.4. Market Estimates & Forecast, by Country, 2023-2032
9.3.4.1.4.1. Germany
9.3.4.1.4.1.1. Market Estimates & Forecast, by Indication, 2023-2032
9.3.4.1.4.1.2. Market Estimates & Forecast, by Age group, 2023-2032
9.3.4.1.4.1.3. Market Estimates & Forecast, by Strength, 2023-2032
9.3.4.1.4.2. France
9.3.4.1.4.2.1. Market Estimates & Forecast, by Indication, 2023-2032
9.3.4.1.4.2.2. Market Estimates & Forecast, by Age group, 2023-2032
9.3.4.1.4.2.3. Market Estimates & Forecast, by Strength, 2023-2032
9.3.4.1.4.3. UK
9.3.4.1.4.3.1. Market Estimates & Forecast, by Indication, 2023-2032
9.3.4.1.4.3.2. Market Estimates & Forecast, by Age group, 2023-2032
9.3.4.1.4.3.3. Market Estimates & Forecast, by Strength, 2023-2032
9.3.4.1.4.4. Italy
9.3.4.1.4.4.1. Market Estimates & Forecast, by Indication, 2023-2032
9.3.4.1.4.4.2. Market Estimates & Forecast, by Age group, 2023-2032
9.3.4.1.4.4.3. Market Estimates & Forecast, by Strength, 2023-2032
9.3.4.1.4.5. Spain
9.3.4.1.4.5.1. Market Estimates & Forecast, by Indication, 2023-2032
9.3.4.1.4.5.2. Market Estimates & Forecast, by Age group, 2023-2032
9.3.4.1.4.5.3. Market Estimates & Forecast, by Strength, 2023-2032
9.3.4.1.4.6. Rest of Western Europe
9.3.4.1.4.6.1. Market Estimates & Forecast, by Indication, 2023-2032
9.3.4.1.4.6.2. Market Estimates & Forecast, by Age group, 2023-2032
9.3.4.1.4.6.3. Market Estimates & Forecast, by Strength, 2023-2032
9.3.5. Eastern Europe
9.3.5.1.1. Market Estimates & Forecast, by Indication, 2023-2032
9.3.5.1.2. Market Estimates & Forecast, by Age group, 2023-2032
9.3.5.1.3. Market Estimates & Forecast, by Strength, 2023-2032
9.4. Asia-Pacific
9.4.1. Market Estimates & Forecast, by Indication, 2023-2032
9.4.2. Market Estimates & Forecast, by Age group, 2023-2032
9.4.3. Market Estimates & Forecast, by Strength, 2023-2032
9.4.4. Market Estimates & Forecast, by Country, 2023-2032
9.4.4.1. China
9.4.4.1.1. Market Estimates & Forecast, by Indication, 2023-2032
9.4.4.1.2. Market Estimates & Forecast, by Age group, 2023-2032
9.4.4.1.3. Market Estimates & Forecast, by Strength, 2023-2032
9.4.4.2. India
9.4.4.2.1. Market Estimates & Forecast, by Indication, 2023-2032
9.4.4.2.2. Market Estimates & Forecast, by Age group, 2023-2032
9.4.4.2.3. Market Estimates & Forecast, by Strength, 2023-2032
9.4.4.3. Japan
9.4.4.3.1. Market Estimates & Forecast, by Indication, 2023-2032
9.4.4.3.2. Market Estimates & Forecast, by Age group, 2023-2032
9.4.4.3.3. Market Estimates & Forecast, by Strength, 2023-2032
9.4.4.4. Australia
9.4.4.4.1. Market Estimates & Forecast, by Indication, 2023-2032
9.4.4.4.2. Market Estimates & Forecast, by Age group, 2023-2032
9.4.4.4.3. Market Estimates & Forecast, by Strength, 2023-2032
9.4.4.5. South Korea
9.4.4.5.1. Market Estimates & Forecast, by Indication, 2023-2032
9.4.4.5.2. Market Estimates & Forecast, by Age group, 2023-2032
9.4.4.5.3. Market Estimates & Forecast, by Strength, 2023-2032
9.4.4.6. Rest of Asia-Pacific
9.4.4.6.1. Market Estimates & Forecast, by Indication, 2023-2032
9.4.4.6.2. Market Estimates & Forecast, by Age group, 2023-2032
9.4.4.6.3. Market Estimates & Forecast, by Strength, 2023-2032
9.5. Middle East & Africa
9.5.1. Market Estimates & Forecast, by Indication, 2023-2032
9.5.2. Market Estimates & Forecast, by Age group, 2023-2032
9.5.3. Market Estimates & Forecast, by Strength, 2023-2032
9.5.4. Market Estimates & Forecast, by Region, 2023-2032
9.5.4.1. Middle East
9.5.4.1.1. Market Estimates & Forecast, by Indication, 2023-2032
9.5.4.1.2. Market Estimates & Forecast, by Age group, 2023-2032
9.5.4.1.3. Market Estimates & Forecast, by Strength, 2023-2032
9.5.4.2. Africa
9.5.4.2.1. Market Estimates & Forecast, by Indication, 2023-2032
9.5.4.2.2. Market Estimates & Forecast, by Age group, 2023-2032
9.5.4.2.3. Market Estimates & Forecast, by Strength, 2023-2032
10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Daptomycin Market
10.5. Competitive Benchmarking
10.6. Leading Player in terms of Number of Developments in Global Daptomycin Market
10.7. Key Developments & Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger & Acquisition
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix & Market Ratio
10.8.1. Sales & Operating Income 2019
10.8.2. Major Players R&D Expenditure 2019
11. COMPANY PROFILES
11.1. Teva Pharmaceutical Industries Ltd.
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Indication Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Merck & Co.
11.3. Cipla
11.4. Pfizer
11.5. BE Pharmaceuticals
11.6. Dr. Reddy's Laboratories
11.7. Mylan
11.8. Fresenius Kabi
11.9. Nichi-Iko Pharmaceutical
11.10. Novo Holdings A/S
11.11. Zhejiang Hisun
11.12. Hengrui Medicine
11.13. Huadong Medicine
11.14. Civica Rx
12. APPENDIX
12.1. References
12.2. Related Reports
12.3. List of Abbreviation
NOTE:
This table of content is tentative and subject to change as the research progresses.
• In section 11, only the top ten companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.
• Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.
Daptomycin Market Segmentation
Daptomycin Indication Outlook (USD Billion, 2018-2032)
Complicated Skin Structure Infections
Bacteremia
Daptomycin Age Group Outlook (USD Billion, 2018-2032)
Pediatric
Adult
Daptomycin Strength Outlook (USD Billion, 2018-2032)
350mg
500mg
Daptomycin Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
North America Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
North America Daptomycin by Age Group
Pediatric
Adult
North America Daptomycin by Strength
350mg
500mg
US Outlook (USD Billion, 2018-2032)
US Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
US Daptomycin by Age Group
Pediatric
Adult
US Daptomycin by Strength
350mg
500mg
CANADA Outlook (USD Billion, 2018-2032)
CANADA Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
CANADA Daptomycin by Age Group
Pediatric
Adult
CANADA Daptomycin by Strength
350mg
500mg
Europe Outlook (USD Billion, 2018-2032)
Europe Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Europe Daptomycin by Age Group
Pediatric
Adult
Europe Daptomycin by Strength
350mg
500mg
Germany Outlook (USD Billion, 2018-2032)
Germany Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Germany Daptomycin by Age Group
Pediatric
Adult
Germany Daptomycin by Strength
350mg
500mg
France Outlook (USD Billion, 2018-2032)
France Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
France Daptomycin by Age Group
Pediatric
Adult
France Daptomycin by Strength
350mg
500mg
UK Outlook (USD Billion, 2018-2032)
UK Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
UK Daptomycin by Age Group
Pediatric
Adult
UK Daptomycin by Strength
350mg
500mg
ITALY Outlook (USD Billion, 2018-2032)
ITALY Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
ITALY Daptomycin by Age Group
Pediatric
Adult
ITALY Daptomycin by Strength
350mg
500mg
SPAIN Outlook (USD Billion, 2018-2032)
Spain Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Spain Daptomycin by Age Group
Pediatric
Adult
Spain Daptomycin by Strength
350mg
500mg
Rest Of Europe Outlook (USD Billion, 2018-2032)
Rest Of Europe Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Rest of Europe Daptomycin by Age Group
Pediatric
Adult
REST OF EUROPE Daptomycin by Strength
350mg
500mg
Asia-Pacific Outlook (USD Billion, 2018-2032)
Asia-Pacific Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Asia-Pacific Daptomycin by Age Group
Pediatric
Adult
Asia-Pacific Daptomycin by Strength
350mg
500mg
China Outlook (USD Billion, 2018-2032)
China Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
China Daptomycin by Age Group
Pediatric
Adult
China Daptomycin by Strength
350mg
500mg
Japan Outlook (USD Billion, 2018-2032)
Japan Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Japan Daptomycin by Age Group
Pediatric
Adult
Japan Daptomycin by Strength
350mg
500mg
India Outlook (USD Billion, 2018-2032)
India Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
India Daptomycin by Age Group
Pediatric
Adult
India Daptomycin by Strength
350mg
500mg
Australia Outlook (USD Billion, 2018-2032)
Australia Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Australia Daptomycin by Age Group
Pediatric
Adult
Australia Daptomycin by Strength
350mg
500mg
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
Rest of Asia-Pacific Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Rest of Asia-Pacific Daptomycin by Age Group
Pediatric
Adult
Rest of Asia-Pacific Daptomycin by Strength
350mg
500mg
Rest of the World Outlook (USD Billion, 2018-2032)
Rest of the World Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Rest of the World Daptomycin by Age Group
Pediatric
Adult
Rest of the World Daptomycin by Strength
350mg
500mg
Middle East Outlook (USD Billion, 2018-2032)
Middle East Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Middle East Daptomycin by Age Group
Pediatric
Adult
Middle East Daptomycin by Strength
350mg
500mg
Africa Outlook (USD Billion, 2018-2032)
Africa Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Africa Daptomycin by Age Group
Pediatric
Adult
Africa Daptomycin by Strength
350mg
500mg
Latin America Outlook (USD Billion, 2018-2032)
Latin America Daptomycin by Indication
Complicated Skin Structure Infections
Bacteremia
Latin America Daptomycin by Age Group
Pediatric
Adult
Latin America Daptomycin by Strength
350mg
500mg